Vertaling van "women per screening " (Frans → Nederlands) :

TERMINOLOGIE

anomalie au screening anténatal de la mère
bevindingen bij prenataal onderzoek, abnormaal

IN-CONTEXT TRANSLATIONS

Biopsy rates are higher among women aged 70 to 79 years (12.2 per 1000 women per screening round) than among younger women. As expected, the number of screen detectedd cancer is highest in this age group.
As expected, the number of screen detectedd cancer is highest in this age group.

screening round). Conversely, false-negative mammography results are a little more common among women aged 70 to 79 years (1.5 per 1000 women per screening round).
Rates of additional imaging are relatively low among women aged 70 to 79 years (64.03 per 1000 women per screening round).

The incidence rate in unscreened women can be observed, as in the control group of a randomised trial, or it can be estimated on the basis of the incidence before screening or in other populations not offered screening 11 .
The incidence rate in unscreened women can be observed, as in the control group of a randomised trial, or it can be estimated on the basis of the incidence before screening or in other populations not offered screening 10 .

Additional diagnostic tests Rates of additional imaging are relatively low among women aged 70 to 79 years (64.03 per 1000 women per screening round).
Biopsy rates are higher among women aged 70 to 79 years (12.2 per 1000 women per screening round) than among younger women.

At the breast screening Most women are nervous, but are not anxious or depressed. Gerard et al. Women from UK aged 40-64
Gerard et al. Women from UK aged 40-64 (1999) 83 EQ-5D years (eligible for screening) UK tariffs (general population) True negative 0.940 At the breast screening Most women are nervous, but are not anxious or depressed. clinic

Table 11: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 22 Study ID study
Table 9: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Crude RR and and RR adjusted following Cuzick (1997) 21 Study ID study

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)